Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

References

• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–3765.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Lavallade H. D, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Goldman JM. Chronic myeloid leukemia: reversing the chronic phase. J Clin Oncol. 2010;28:363–365.
   PubMedGoogle Scholar
• Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519–7527.
   PubMed Web of Science ®Google Scholar
• La Rosée P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol. 2010;47:335–343.
   PubMed Web of Science ®Google Scholar
• Gotta V, Buclin T, Csajka C, et al. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit. 2013;35:150–167.
   PubMed Web of Science ®Google Scholar
• Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74:1307–1319.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–408.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003;4:75–85.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009;23:1537–1544.
   PubMed Web of Science ®Google Scholar
• Herviou P, Thivat E, Richard D, et al. Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett. 2016;12:1223–1232.
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–3499.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–4028.
   PubMed Web of Science ®Google Scholar
• Gotta V, Bouchet S, Widmer N, et al. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res. 2014;38:764–772.
   PubMed Web of Science ®Google Scholar
• Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008;98:1633–1640.
   PubMed Web of Science ®Google Scholar
• Zhong J-S, Meng F-Y, Xu D, et al. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol. 2012;127:221–227.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther. 2010;88:809–813.
   PubMed Web of Science ®Google Scholar
• Yoshida C, Komeno T, Hori M, et al. Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol. 2011;93:618–623.
   PubMed Web of Science ®Google Scholar
• Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009;33:271–275.
   PubMed Web of Science ®Google Scholar
• Faber E, Friedecký D, Mičová K, et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol. 2012;91:923–929.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Chronic Myelogenous Leukemia; Version 1.2016 [Internet]. National Comprehensive Cancer Network; 2016 [cited 2016 Feb 20]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#cml.
   Google Scholar
• Bakhtiar R, Lohne J, Ramos L, et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;768:325–340.
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar L, Meena R, et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65:545–549.
   PubMed Web of Science ®Google Scholar
• Wallemacq P. Therapeutic drug monitoring of imatinib. Rev Bras Hematol Hemoter. 2011;33:257–258.
   PubMedGoogle Scholar
• Harivenkatesh N, Kumar L, Bakhshi S, et al. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacol Res. 2017;120:138–145.
   PubMed Web of Science ®Google Scholar
• Harivenkatesh N, Kumar L, Bakhshi S, et al. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leuk Lymphoma. 2017;58:1–9.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology. 2011;87:241–248.
   PubMed Web of Science ®Google Scholar
• Arora B, Gota V, Menon H, et al. Therapeutic drug monitoring for imatinib: current status and Indian experience. Indian J Med Paediatr Oncol. 2013;34:224–228.
   PubMedGoogle Scholar
• Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012;97:731–738.
   PubMed Web of Science ®Google Scholar
• Koren-Michowitz M, Volchek Y, Naparstek E, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012;30:200–205.
   PubMed Web of Science ®Google Scholar
• Sohn SK, Oh SJ, Kim BS, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 2011;52:1024–1029.
   PubMed Web of Science ®Google Scholar
• Malhotra H, Sharma P, Bhargava S, et al. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55:2614–2619.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kiyoi H, Watanabe K, et al. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci. 2010;101:2186–2192.
   PubMed Web of Science ®Google Scholar